{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:46:32Z","timestamp":1790700392432,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.ejca.2013.05.011","type":"journal-article","created":{"date-parts":[[2013,6,10]],"date-time":"2013-06-10T12:15:40Z","timestamp":1370866540000},"page":"2832-2840","source":"Crossref","is-referenced-by-count":33,"title":["A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation"],"prefix":"10.1016","volume":"49","clinical-trial-number":[{"clinical-trial-number":"nct01465464","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yoshitaka","family":"Inaba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Aramaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanobu","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Yamakado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuho","family":"Imanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Kora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Arioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2013.05.011_b0005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2013.05.011_b0010","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S1665-2681(19)31650-3","article-title":"Prevention of hepatocellular carcinoma","volume":"9","author":"Kew","year":"2010","journal-title":"Ann Hepatol"},{"issue":"Suppl.","key":"10.1016\/j.ejca.2013.05.011_b0015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1665-2681(19)31736-3","article-title":"And hepatocellular carcinoma","volume":"9","author":"Fassio","year":"2010","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.ejca.2013.05.011_b0020","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1038\/sj.onc.1209562","article-title":"Viral hepatitis and liver cancer: the case of hepatitis C","volume":"25","author":"Levrero","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2013.05.011_b0025","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2013.05.011_b0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2013.05.011_b0035","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2013.05.011_b0040","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.ejca.2013.05.011_b0045","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Management of hepatocellular carcinoma","volume":"42","author":"Bruix","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.ejca.2013.05.011_b0050","first-page":"4152","article-title":"SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors","volume":"60","author":"Laird","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2013.05.011_b0055","first-page":"7048","article-title":"In vivo intracellular signaling as a marker of antiangiogenic activity","volume":"61","author":"Solorzano","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2013.05.011_b0060","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.1158\/1078-0432.CCR-04-2466","article-title":"Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies","volume":"11","author":"Kuenen","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2013.05.011_b0065","first-page":"677","article-title":"TSU-68 (SU6668) inhibits local tumor growth and liver metastasis of human colon cancer xenografts via anti-angiogenesis","volume":"14","author":"Yorozuya","year":"2005","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ejca.2013.05.011_b0070","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1158\/1078-0432.CCR-05-1615","article-title":"The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis","volume":"12","author":"Naumova","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2013.05.011_b0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00280-010-1320-2","article-title":"A phase I\/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma","volume":"67","author":"Kanai","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2013.05.011_b0080","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lenchioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.ejca.2013.05.011_b0085","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jhep.2011.03.007","article-title":"EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization","volume":"55","author":"Gillmore","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2013.05.011_b0090","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1386-6346(02)00144-4","article-title":"Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis","volume":"24","author":"Ueno","year":"2002","journal-title":"Hepatol Res"},{"key":"10.1016\/j.ejca.2013.05.011_b0095","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.ejca.2013.05.011_b0100","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1200\/JCO.2010.28.7805","article-title":"Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.05.011_b0105","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ctrv.2011.05.002","article-title":"Locoregional radiological treatment for hepatocellular carcinoma; which, when and how?","volume":"38","author":"Meza-Junco","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2013.05.011_b0110","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S1470-2045(09)70171-8","article-title":"Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study","volume":"10","author":"Faivre","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2013.05.011_b0115","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.ejca.2011.05.007","article-title":"Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma","volume":"47","author":"Kudo","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2013.05.011_b0120","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1572-0241.2007.01712.x","article-title":"Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness","volume":"103","author":"Sergio","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejca.2013.05.011_b0125","first-page":"1087","article-title":"Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of hepatocellular carcinoma","volume":"14","author":"Suzuki","year":"1999","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ejca.2013.05.011_b0130","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.3748\/wjg.v10.i19.2878","article-title":"Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level","volume":"10","author":"Li","year":"2004","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejca.2013.05.011_b0135","first-page":"1077","article-title":"High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study","volume":"11","author":"Poon","year":"2004","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ejca.2013.05.011_b0140","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1515\/CCLM.2010.278","article-title":"Serum soluble tumour necrosis factor receptor type I concentrations independently predict prognosis in patients with breast cancer","volume":"48","author":"Fuksiewicz","year":"2010","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.ejca.2013.05.011_b0145","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1007\/DCR.0b013e3181a0d144","article-title":"Serum level of soluble vascular cell adhesion molecule 1 is a valuable prognostic marker in colorectal carcinoma","volume":"52","author":"Okugawa","year":"2009","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.ejca.2013.05.011_b0150","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/157488408784293705","article-title":"The molecular basis of class side effects due to treatment with inhibitors of the VEGF\/VEGFR pathway","volume":"3","author":"Roodhart","year":"2008","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.ejca.2013.05.011_b0155","doi-asserted-by":"crossref","first-page":"8557","DOI":"10.1158\/1078-0432.CCR-05-0944","article-title":"Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential","volume":"11","author":"Zhang","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2013.05.011_b0160","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1016\/S0959-8049(02)00218-6","article-title":"Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma","volume":"38","author":"O\u2019Hanlon","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2013.05.011_b0165","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1572-0241.2003.07259.x","article-title":"Clinical significance of serum levels of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in gastric cancer patients","volume":"98","author":"Alexiou","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejca.2013.05.011_b0170","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3390\/ph3030572","article-title":"Platelet-derived growth factor (PDGF)\/PDGF receptors (PDGFR) axis as target for antitumor and antiangiogenic therapy","volume":"3","author":"Raica","year":"2010","journal-title":"Pharmaceuticals"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913004085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913004085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T02:34:10Z","timestamp":1563158050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804913004085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":34,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0959804913004085"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2013.05.011","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}